|Bid||20.90 x 2200|
|Ask||21.80 x 800|
|Day's Range||21.15 - 21.95|
|52 Week Range||9.87 - 32.74|
|Beta (3Y Monthly)||1.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.09|
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in MacroGenics, Inc. (NASDAQ:MGNX) have powerRead More...
Soft demand pattern in voice and video businesses, along with decline in switched access are likely to take a toll on Frontier Communications' (FTR) fourth-quarter revenues.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that on Tuesday, February 26, 2019, the Company will release its financial results for the fourth quarter and full year 2018. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Tuesday, February 26, 2019 at 4:30 pm ET. The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm.
Solid domestic site leasing business, excellent services and cost control initiatives are likely to drive SBA Communications' (SBAC) fourth-quarter earnings.
Telefonica Brasil's (VIV) fourth-quarter earnings are likely to benefit from its asset base and solid position in key high-value segments.
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
There are dozens of listed biotech and pharmaceutical companies with scant revenues that have managed to carry out public offerings to raise funding purely for research. MacroGenics Inc. (MGNX) is a classic example of one such company. With the recent spike in its stock price, and its upcoming offering, the stock is an excellent subject of analysis.
ROCKVILLE, MD, Feb. 13, 2019 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. MacroGenics anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $110 million, excluding any exercise of the underwriters’ option to purchase additional shares.
MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten public offering of shares of its common stock pursuant to its existing shelf registration statement. MacroGenics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. The shares are being offered by MacroGenics pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
Positive trial results for a cancer drug boost shares by 130% in one day. Time for newer investors in the stock to take chips off the table?
MacroGenics Rose 130.42% on February 6Share price movements On February 6, MacroGenics (MGNX) closed at $25.60, which is 130.42% higher than the previous closing price, 159.37% higher than its 52-week low of $9.87, and 21.81% below its 52-week high
The successful late-stage trial is a big victory for the Rockville biotech, which focuses on antibody-based therapeutics to treat cancer.
Nomura sees the stock between $19 and $28 on positive Sophia results, Bloomberg says. Nomera and Leerink played lead roles in MacroGenics' public offering of 4,500,000 common shares priced at $21.25 in March 2018.
Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.
A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...
The latest big move in a volatile year for MacroGenics highlights the outsize risks and potential benefits of investing in clinical-stage biotech startups.
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.